Skip to main
ALZN
ALZN logo

Alzamend Neuro (ALZN) Stock Forecast & Price Target

Alzamend Neuro (ALZN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alzamend Neuro Inc. has demonstrated a positive trajectory in its clinical development, notably reporting positive top-line results in June 2023 for its therapeutic candidates, which support their innovative approach to treating neurodegenerative diseases and psychiatric disorders. The company's unique offerings, AL001 and AL002, leverage patented technologies expected to enhance the efficacy of treatments for Alzheimer's, a critical area in need of effective solutions. Furthermore, the current valuation of Alzamend Neuro is considered attractive, with potential for significant upside based on a net present value analysis, suggesting that successful achievement of upcoming milestones could act as positive catalysts for the stock's performance.

Bears say

Alzamend Neuro Inc reported a net loss of $2.7 million, translating to an earnings per share (EPS) of $(1.28), which significantly undershot estimates of $(0.69). The company's clinical-stage pipeline, while ambitious, faces substantial risks, including potential failures in demonstrating product safety and efficacy, regulatory approval challenges, and commercialization hurdles. Additional concerns stem from balance sheet and liquidity risks, heightened competition, and broader macroeconomic factors that could adversely affect investor sentiment towards biotechnology stocks.

Alzamend Neuro (ALZN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alzamend Neuro (ALZN) Forecast

Analysts have given Alzamend Neuro (ALZN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Alzamend Neuro (ALZN) has a Strong Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alzamend Neuro (ALZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.